MRNA Oct 2022 175.000 put
| Previous close | 59.48 |
| Open | 58.63 |
| Bid | 41.30 |
| Ask | 41.60 |
| Strike | 175.00 |
| Expiry date | 2022-10-21 |
| Day's range | 58.63 - 59.48 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
- Editor's pickYahoo Finance
Omicron: Experts want more data to guide US targeting of fall boosters
The FDA is asking COVID-19 vaccine makers to test and produce boosters that target both the original and new BA.4/BA.5 strains of the virus by fall.
- Motley Fool
Could This Send Moderna's Stock Soaring Back to $400?
Shares of Moderna (NASDAQ: MRNA) have been plummeting in recent months. As concerns shift from COVID-19 and onto inflation, investors have become less bullish on Moderna's stock. Omicron was a significant variant when it emerged in November, and that prompted Moderna to create a booster shot which targeted that variant.
- Motley Fool
3 Things About Moderna That Smart Investors Know
Prior to the pandemic, Moderna (NASDAQ: MRNA) was like many other small biotechs. In fact, for the full year of 2019, Moderna had only $60 million in revenue, entirely from collaborations and grants, and it posted a net loss of $514 million. As we know, Moderna's ability to rapidly produce a vaccine for the COVID-19 virus changed the financial prospects for the company and put it in a completely different position today.
